Skip to main content
. Author manuscript; available in PMC: 2006 Nov 21.
Published in final edited form as: J Biol Chem. 2006 Mar 30;281(23):15941–15950. doi: 10.1074/jbc.M512586200

FIGURE 7. Differential interactions of Bax with Bcl-xL but not Bcl-2.

FIGURE 7

A, KB-3 cells were untreated (lanes 1–3) or treated with vinblastine (VBL, 30 nM, 36 h, lanes 4 – 6) and Bcl-2 was immunoprecipitated (IP), as described under “Experimental Procedures.” Immunoprecipitations were performed with (+Ab, lanes 2 and 5) or without (−Ab, lanes 3 and 6) the relevant primary antibody as indicated. Whole cell extracts were also analyzed (lanes 1 and 4). The samples were analyzed by immunoblotting for Bcl-2 (top panel) or Bax (lower panel). B, KB-3 cells were treated with 30 nM vinblastine (VBL) for the times indicated and subjected to immunoprecipitation (IP) with anti-Bcl-xL antibody (lanes 3, 6, and 9), followed by immunoblotting for Bcl-xL (top panel) or Bax (lower panel) as indicated. Precipitates prepared in the absence of primary antibody (lanes 2, 5, and 8) and whole cell extracts (lanes 1, 4, and 7) were also examined as controls. C, KB-3 cells were treated with 30 nM vinblastine (VBL) for the times indicated and subjected to immunoprecipitation (IP) with anti-Bax 6A7 antibody (lanes 2, 5, and 8), followed by immunoblotting for Bax (top panel) or Bcl-xL (lower panel) as indicated. Precipitates prepared in the absence of primary antibody (lanes 3, 6, and 9) and whole cell extracts (lanes 1, 4, and 7) were also examined as controls.